cancer

envie a um amigo share this

Conversation with James Allison from the JCI series «Conversations with Giants in Medicine»

We decided to republish in ASPIC's website the interview below:

 

 

Interview with James Allison of the MD Anderson Cancer Center, who has made key discoveries on the regulation of T cell activation and modulation. He was awarded the 2015 Lasker DeBakey Clinical Medical Research Award in honor of his discovery and subsequent development of CTLA-4–targeted monoclonal antibody therapy to unleash the immune response to cancer.

 

See the interview here: http://www.jci.org/videos/104

Conversation with James Allison from the JCI series «Conversations with Giants in Medicine»

We decided to republish in ASPIC's website the interview below:

 

 

Interview with James Allison of the MD Anderson Cancer Center, who has made key discoveries on the regulation of T cell activation and modulation. He was awarded the 2015 Lasker DeBakey Clinical Medical Research Award in honor of his discovery and subsequent development of CTLA-4–targeted monoclonal antibody therapy to unleash the immune response to cancer.

 

See the interview here: http://www.jci.org/videos/104

DNA Damage, Mutation & Cancer: Genome Instability from Environmental and Inherent Sources of DNA Damage

Ventura Beach Marriott, Ventura, CA, United States

 

13 - 18 March, 2016

 

See more informations here: http://www.grc.org/programs.aspx?id=12940

Cancer incidence will keep rising up to 2020, in the North Region of Portugal

Cancer incidence will keep rising up to 2020, in the North Region of Portugal. According to the North Region Cancer Registry (RORENO), 10236 new cases will be diagnosed in that year. Women will experience the steepest increase, mainly due to thyroid and lung cancers. For the same period, a decreasing trend in the number of new cases is expected for cancer of the cervix. This study contributed to a broader understanding of the population’s cancer burden, useful for the implementation of cancer control measures.

 

Authors and Affiliations:

Supramolecular nanoscale assemblies for cancer diagnosis and therapy

Authors and Affiliations:

Sílvia Castro Coelho1, Maria Carmo Pereira1, Asta Juzeniene2, Petras Juzenas2, Manuel Álvaro Coelho1

 1 LEPABE, Department of Chemical Engineering, Faculty of Engineering, University of Porto, Rua Roberto Frias, PT-4200-465 Porto, Portugal

2 Department of Radiation Biology, Institute for Cancer Research, Radiumhospital, Oslo University Hospital, NO-0310 Oslo, Norway

 

Abstract:

First International Symposium on the Impact of Occupational Exposures on DNA Stability and Human Cancer Risks

HSZ Hörsaalzentrum der Medizinischen Universität Graz, Graz, Austria

 

12 September 2015

 

See more informations here: http://www.eacr.org/user_uploads/files/meetings/Graz%2012-9-2015.pdf

First International Symposium on the Impact of Occupational Exposures on DNA Stability and Human Cancer Risks

HSZ Hörsaalzentrum der Medizinischen Universität Graz, Graz, Austria

 

12 September 2015

 

See more informations here: http://www.eacr.org/user_uploads/files/meetings/Graz%2012-9-2015.pdf

Molecule patented by the University of Coimbra for innovative therapy in the treatment of several types of cancer reveals efficacy

Authors and Affiliations:

Luis B. Rochaa, Lígia C. Gomes-da-Silvab, Janusz M. Dąbrowskic, Luis G. Arnauta,b

a Luzitin SA, R. Bayer, S. Martinho do Bispo, 3045-016 Coimbra, Portugal

b Chemistry Department, University of Coimbra, 3004-535 Coimbra, Portugal

c Faculty of Chemistry, Jagiellonian University, 30-060 Kraków, Poland

 

Abstract:

Molécula patenteada pela Universidade de Coimbra para terapia inovadora no tratamento de vários tipos de cancro revela a eficácia desejada

Vários estudos e experiências realizadas em ratinhos, entre 2011 e 2014, provaram a eficácia da molécula Redaporfin, descoberta na Universidade de Coimbra (UC) para o tratamento de vários tipos de cancro através de terapia fotodinâmica, uma terapia inovadora que permite eliminar as células cancerígenas de forma precisa.

Overexpression of pyruvate dehydrogenase kinase supports DCA as a candidate for cutaneous melanoma therapy

DCA was proposed as a possible cancer therapy, although it was unknown its possible use as cutaneous melanoma therapy. A team of IPATIMUP researchers published a study in Expert Opinion on Therapeutic Targets, where they evaluated the expression profile of pyruvate dehydrogenase kinase isoforms, the DCA targets, in a series of melanoma samples and nevi, and also established the sensitivity of melanoma cell lines to DCA treatment.